Baxalta Ventures

Baxalta Ventures is the corporate venture capital arm of Baxalta with over $200 million under management, and is a core facet of Baxalta’s R&D strategy.

Our investment approach is primarily focused on accelerating development of cutting-edge innovative biotechnologies that address unmet patient needs in hematology, immunology and oncology.

Baxalta’s commitment to strive for excellence on behalf of patients, caregivers and healthcare providers is at the center of every investment we make.

Investment Approach

  • Baxalta Ventures is focused on fostering relationships. We believe that long-term success of our investments is best achieved by cultivating strong ties with entrepreneurs, fellow investors and industry experts.
  • Through strong industry networks, active board representation, and leveraging Baxalta’s product development and commercialization expertise, we aim to maximize value creation in our portfolio companies.
  • We are stage and series agnostic and can lead financing rounds or join established investment syndicates with an initial investment of about $5 million, while reserving capital for follow-on rounds.

Areas of Interest

We align our focus with Baxalta’s core businesses, directing our investment interests toward novel therapeutics, select diagnostics, IT solutions and leading-edge technology platforms that address disease management in these key therapeutic areas:

  • Hematology
  • Immunology
  • Oncology

Investment Team

Geeta Vemuri, PhD, MBA: Managing Partner
Geeta Vemuri
  • Current board responsibilities: Aptinyx, Gadeta, Syntimmune, Tiatros, True North Therapeutics, Vitesse Biologics
  • Previously:
    • Managing Partner at Baxter Ventures
    • Partner at Quaker Partners
    • Associate at Toucan Capital and Salomon Smith Barney
  • Select previous board responsibilities: Covagen (acq. Janssen), Cempra (NASDQ: CEMP), Naurex (acq. Allergan), Ocular Therapeutix (NASDQ: OCUL)
  • Education: PhD in biochemistry from Indian Institute of Sciences, MBA from Wharton School of Business
Amanda Hayward, PhD: Partner
Amanda Hayward
  • Current board observation responsibilities: Vitesse Biologics
  • Previously:
    • Senior Vice President at Scheer and Company
    • Co-Founder and acting CFO at Axerion Therapeutics, Optherion Therapeutics, Tengion, Aegerion and Sopherion Therapeutics
    • Bristol-Myers Squibb postdoctoral fellow at Yale University
  • Previous board responsibilities: Axerion Therapeutics, Optherion Therapeutics
  • Education: PhD in anatomy, cell biology and molecular genetics from Texas Tech University
Marta New, PhD, MBA: Principal
Marta New
  • Current board observation responsibilities: Gadeta, Syntimmune, Vitesse Biologics
  • Previously:
    • Senior Associate at Baxter Ventures
    • Senior Marketing Manager at Baxter Healthcare
    • Entrepreneur-in-Residence at the New Ventures Office at Northwestern University
    • Postdoctoral fellow in oncology and immunology at Northwestern University
  • Education: PhD in microbiology and immunology from University of Illinois at Chicago, MBA from the Kellogg School of Management
Preston Noon, PharmD, MBA: Senior Analyst
Preston Noon
  • Previously:
    • Business development and licensing Associate at Bayer Healthcare Pharmaceuticals
    • Medical Affairs Analyst for recruitment strategy and analytics at Bristol-Myers Squibb
  • Education: PharmD and MBA from University of Connecticut

Contact Us

Baxalta Ventures
650 E Kendall Street
Cambridge, MA 02142
617-588-8441
www.baxalta.com/ventures

Click here to apply for funding